Absence of Mutations in Cereblon (CRBN) and DNA Damage-binding Protein 1 (DDB1) Genes and Significance for IMiD Therapy

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2013 Oct 30

PMID 24166296

Citations 33

Authors

A Thakurta

A K Gandhi

M F Waldman

C Bjorklund

Y Ning

D Mendy

P Schafer

A Lopez-Girona

S Lentzsch

S A Schey

Y Calle

R Chelliah

R Z Orlowski

A Madan

H Avet-Loiseau

R Chopra

Affiliations

Soon will be listed here.

Citing Articles

Impact of Genetic Polymorphisms on Treatment Outcomes of Proteasome Inhibitors and Immunomodulatory Drugs in Multiple Myeloma.

Karimi F, Aghaei M, Saki N Curr Treat Options Oncol. 2025; .

PMID: 40042740 DOI: 10.1007/s11864-025-01295-8.

Cereblon regulates the production of hepatic fibroblast growth factor 23 in diabetes.

An S, Nedumaran B, Oh H, Park T, Park C, Djalilian A BMB Rep. 2024; 57(12):533-538.

PMID: 39384178 PMC: 11693598.

Preclinical Evaluation of a Novel Series of Polyfluorinated Thalidomide Analogs in Drug-Resistant Multiple Myeloma.

Barton B, Collins M, Chau C, Choo-Wosoba H, Venzon D, Steinebach C Biomolecules. 2024; 14(6).

PMID: 38927128 PMC: 11201495. DOI: 10.3390/biom14060725.

Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma.

Amatangelo M, Flynt E, Stong N, Ray P, Van Oekelen O, Wang M Cell Rep Med. 2024; 5(6):101571.

PMID: 38776914 PMC: 11228401. DOI: 10.1016/j.xcrm.2024.101571.

Induced protein degradation for therapeutics: past, present, and future.

Yoon H, Rutter J, Li Y, Ebert B J Clin Invest. 2024; 134(1).

PMID: 38165043 PMC: 10760958. DOI: 10.1172/JCI175265.

References

Heintel D, Rocci A, Ludwig H, Bolomsky A, Caltagirone S, Schreder M . High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol. 2013; 161(5):695-700. DOI: 10.1111/bjh.12338. View

Higgins J, Pucilowska J, Lombardi R, Rooney J . A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology. 2004; 63(10):1927-31. PMC: 1201536. DOI: 10.1212/01.wnl.0000146196.01316.a2. View

Gandhi A, Mendy D, Waldman M, Chen G, Rychak E, Miller K . Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol. 2013; 164(2):233-44. PMC: 4253085. DOI: 10.1111/bjh.12622. View

Schuster S, Kortuem K, Zhu Y, Braggio E, Shi C, Bruins L . The clinical significance of cereblon expression in multiple myeloma. Leuk Res. 2013; 38(1):23-8. PMC: 3905958. DOI: 10.1016/j.leukres.2013.08.015. View

Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi A, Kang J . Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012; 26(11):2326-35. PMC: 3496085. DOI: 10.1038/leu.2012.119. View

Broyl A, Kuiper R, van Duin M, van der Holt B, El Jarari L, Bertsch U . High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood. 2012; 121(4):624-7. DOI: 10.1182/blood-2012-06-438101. View

Zhu Y, Braggio E, Shi C, Bruins L, Schmidt J, Van Wier S . Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011; 118(18):4771-9. PMC: 3208291. DOI: 10.1182/blood-2011-05-356063. View

Sardnal V, Rouquette A, Kaltenbach S, Bally C, Chesnais V, Leschi C . A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). Leukemia. 2013; 27(7):1610-3. DOI: 10.1038/leu.2013.59. View

Chapman M, Lawrence M, Keats J, Cibulskis K, Sougnez C, Schinzel A . Initial genome sequencing and analysis of multiple myeloma. Nature. 2011; 471(7339):467-72. PMC: 3560292. DOI: 10.1038/nature09837. View

10.

Egan J, Kortuem K, Kurdoglu A, Izatt T, Aldrich J, Reiman R . Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease. Br J Haematol. 2013; 161(5):748-751. PMC: 3655110. DOI: 10.1111/bjh.12291. View

11.

Lode L, Amiot M, Maiga S, Touzeau C, Menard A, Magrangeas F . Cereblon expression in multiple myeloma: not ready for prime time. Br J Haematol. 2013; 163(2):282-4. DOI: 10.1111/bjh.12478. View

12.

Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y . Identification of a primary target of thalidomide teratogenicity. Science. 2010; 327(5971):1345-50. DOI: 10.1126/science.1177319. View